scPharmaceuticals (NASDAQ:SCPH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a report issued on Monday,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock.

Separately, Craig Hallum cut their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

scPharmaceuticals Stock Down 2.1 %

Shares of NASDAQ SCPH opened at $3.21 on Monday. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The firm has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $3.99. The firm has a market capitalization of $160.63 million, a PE ratio of -1.69 and a beta of 0.11. scPharmaceuticals has a 12 month low of $3.08 and a 12 month high of $6.20.

Institutional Investors Weigh In On scPharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC bought a new stake in shares of scPharmaceuticals during the third quarter valued at approximately $9,343,000. Rubric Capital Management LP grew its holdings in shares of scPharmaceuticals by 35.5% in the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after purchasing an additional 1,250,000 shares in the last quarter. King Luther Capital Management Corp grew its holdings in shares of scPharmaceuticals by 28.4% in the fourth quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock valued at $10,117,000 after purchasing an additional 632,120 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in shares of scPharmaceuticals by 59.2% in the fourth quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock valued at $3,503,000 after purchasing an additional 367,970 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its stake in scPharmaceuticals by 84.7% during the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after buying an additional 357,171 shares during the period. Institutional investors own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.